These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
959 related articles for article (PubMed ID: 18997056)
21. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607 [TBL] [Abstract][Full Text] [Related]
22. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. Ho CL; Yu SC; Yeung DW J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212 [TBL] [Abstract][Full Text] [Related]
23. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Metser U; Even-Sapir E Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153 [TBL] [Abstract][Full Text] [Related]
24. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma. Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642 [TBL] [Abstract][Full Text] [Related]
25. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635 [TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821 [TBL] [Abstract][Full Text] [Related]
27. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer. Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990 [TBL] [Abstract][Full Text] [Related]
28. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer. Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838 [TBL] [Abstract][Full Text] [Related]
29. Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT. Choi JW; Yoon YH; Yoon YH; Kim SM; Koo BS Ann Surg Oncol; 2011 May; 18(5):1306-11. PubMed ID: 21140231 [TBL] [Abstract][Full Text] [Related]
30. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925 [TBL] [Abstract][Full Text] [Related]
31. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. Saif MW; Cornfeld D; Modarresifar H; Ojha B J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269 [TBL] [Abstract][Full Text] [Related]
33. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207 [TBL] [Abstract][Full Text] [Related]
34. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Kim SJ; Lee TH; Kim IJ; Kim YK Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685 [TBL] [Abstract][Full Text] [Related]
35. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409 [TBL] [Abstract][Full Text] [Related]
36. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. Kim SY; Roh JL; Kim MR; Kim JS; Choi SH; Nam SY; Lee SW; Kim SB J Nucl Med; 2007 May; 48(5):752-7. PubMed ID: 17475963 [TBL] [Abstract][Full Text] [Related]
37. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Seo S; Hatano E; Higashi T; Hara T; Tada M; Tamaki N; Iwaisako K; Ikai I; Uemoto S Clin Cancer Res; 2007 Jan; 13(2 Pt 1):427-33. PubMed ID: 17255262 [TBL] [Abstract][Full Text] [Related]
38. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862 [TBL] [Abstract][Full Text] [Related]
40. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]